Knopp Neurosciences has noted encouraging clinical results in a Phase 2 study of KNS-760704 for ALS, showing that the drug was safe and well-tolerated for up to nine months. These results were presented at the 20th International Symposium on ALS/MND in Berlin, Germany. Study trends also suggested potentially beneficial outcomes in function and survival. “Knopp is very encouraged by the results presented today in Berlin and, at the same time, we’re acutely aware of the work that remains to be done” said Michael Bozik, M.D., the President and CEO of Knopp. The company has engaged US and EU regulators for its planned Phase 3 program.
Click here to read more.Share this: